

**From:** The Office of [REDACTED] [JJCUS] [REDACTED]@prdus.jnj.com>  
**Sent:** 17 June 2020 13:14  
**To:** GAUER Celine (SG-RECOVER)  
**Cc:** VANDENBERGHE Kurt (CAB-VON DER LEYEN)  
**Subject:** Term Sheet Commission/Alliance  
**Attachments:** EC-IVA term sheet 17.06.2020 (clin1) (003).docx

**Categories:** TO REGISTER

Dear Mrs Gauer

Many thanks for the very helpful discussion we had yesterday.

Please see attached the term sheet as referred to in the call. It reflects the proposal we presented to you.

This term sheet is addressed again to both the Commission and the Inclusive Vaccine Alliance, for transparency and speed of communication. This explains also why in this term sheet we have included both a) supply of vaccine to resourced-limited settings, and b) the proposal on financing of manufacturing capacity, as requested by the Alliance.

On your question about the scientific basis of the down payments, these are indeed linked to indicative timepoints of clinical data becoming available:

- Interim Phase 1 data on our vaccine candidate (immunogenicity and safety data, post second dose) are expected to be available before [REDACTED]
- Interim safety and efficacy data from Phase 3 study are expected to become available before [REDACTED]

We will follow-up on the remaining outstanding questions as soon as possible.

Kindly include any suggested edits you may have directly in the document. In order to maintain momentum, would you be able revert to us before the end of today?

Much looking forward to finalize an agreement with you soonest.

Best regards,

[REDACTED]